Thanh Loc Nguyen
Research Subjects
Thanh Loc Nguyen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Jaeyun Kim
School of Chemical Engineering Sungkyunkwan University (SKKU) Suwon Republic of Korea
7 shared publications Ngoc Man Phan
School of Chemical Engineering
5 shared publicationsXin Wang Mo
School of Chemical Engineering
3 shared publications- Cuong Hung Luu
School of Environment and Science, Griffith University, Nathan, QLD 4111, Australia
2 shared publications - Doo Sung Lee
School of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Gyeonggi-do, Republic of Korea
2 shared publications - Duy-Khiet Ho
Department of Bioengineering, University of Washington, Seattle, WA 98195, USA
2 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1312
Correction: Phan et al. Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment. Pharmaceutics 2022, 14, 709
- 16 October 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1312
Open AccessCorrection: Phan et al. Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment. Pharmaceutics 2022, 14, 709
- 19 May 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (21) , 15008-15021
Engineered 3D-Lattice Microneedle Array Patches for Enhanced Nanovaccine Delivery to Dendritic Cells in Cancer Immunotherapy
Cancer vaccines are designed to activate dendritic cells (DCs), which are potent antigen-presenting cells that initiate antigen-specific adaptive immune responses and inhibit tumor growth. Microneedles (MNs) have emerged as a promising cancer vaccine platform, enabling the noninvasive dermal delivery of cancer antigens and adjuvants to activate dermal DCs. However, conventional solid MNs have a limited surface area, restricting the adsorption of large amounts of bioactive components. Therefore, 3D-printed lattice-structured microarray patches (L-MAPs) with an increased surface area were designed in this study, which permitted the enhanced adsorption of cancer nanovaccines compared to conventional solid microarray patches. L-MAPs were fabricated by using the continuous liquid interface production (CLIP) technology, facilitating the rapid printing of MNs with lattice structures. L-MAPs adsorbed higher amounts of mesoporous-silica-based nanovaccine (MV) on their needle surfaces, exhibiting greater dermal vaccine delivery capacity. Applying MV@MAPs on mouse skin led to efficient DC recruitment, maturation, and subsequent antigen-specific T cell responses in vivo. Consequently, the resulting antitumor immune response considerably suppressed the tumor growth. This approach highlights that using CLIP-printed L-MAPs is a promising strategy for efficient nanovaccine delivery in cancer immunotherapies.
- 19 May 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (21) , 15008-15021
Engineered 3D-Lattice Microneedle Array Patches for Enhanced Nanovaccine Delivery to Dendritic Cells in Cancer Immunotherapy
Cancer vaccines are designed to activate dendritic cells (DCs), which are potent antigen-presenting cells that initiate antigen-specific adaptive immune responses and inhibit tumor growth. Microneedles (MNs) have emerged as a promising cancer vaccine platform, enabling the noninvasive dermal delivery of cancer antigens and adjuvants to activate dermal DCs. However, conventional solid MNs have a limited surface area, restricting the adsorption of large amounts of bioactive components. Therefore, 3D-printed lattice-structured microarray patches (L-MAPs) with an increased surface area were designed in this study, which permitted the enhanced adsorption of cancer nanovaccines compared to conventional solid microarray patches. L-MAPs were fabricated by using the continuous liquid interface production (CLIP) technology, facilitating the rapid printing of MNs with lattice structures. L-MAPs adsorbed higher amounts of mesoporous-silica-based nanovaccine (MV) on their needle surfaces, exhibiting greater dermal vaccine delivery capacity. Applying MV@MAPs on mouse skin led to efficient DC recruitment, maturation, and subsequent antigen-specific T cell responses in vivo. Consequently, the resulting antitumor immune response considerably suppressed the tumor growth. This approach highlights that using CLIP-printed L-MAPs is a promising strategy for efficient nanovaccine delivery in cancer immunotherapies.
- 11 December 2025
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (1) , 121-133
Antioxidant Hydrogel-Based Transdermal Drug Delivery Patch for Reactive Oxygen Species- and MyD88-Targeted Management of Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disorder driven by skin barrier dysfunction, immune dysregulation, a self-perpetuating cycle of inflammation and oxidative stress. Current therapies often target either oxidative stress or inflammation, yielding suboptimal outcomes. To overcome this, we developed Ce@iMyD88, a synergistic nanozyme, conjugating mesoporous cerium oxide nanoparticles with a MyD88 inhibitor (iMyD88), engineered to simultaneously scavenge reactive oxygen species (ROS) and suppress MyD88/NF-κB-mediated inflammatory signaling. Encapsulation in a lignin-based hydrogel provided biocompatibility, stability, and intrinsic antioxidant properties. In vitro, Ce@iMyD88 neutralizes superoxide, hydrogen peroxide, hydroxyl radicals, and attenuated ROS/proinflammatory cytokine expression in 2,4-dinitrochlorobenzene (DNCB)/H2O2-stimulated HaCaT keratinocytes. In vivo, applications in DNCB-induced AD and H2O2-challenged mice reduced epidermal thickness, mast cell infiltration, and restored skin barrier integrity. Compared with monotherapies, Ce@iMyD88 hydrogels markedly alleviated oxidative stress and inhibited MyD88/NF-κB signaling, reducing lesion severity and providing a precise strategy for managing inflammatory skin diseases through integrated nanoscale interventions.
- 11 December 2025
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (1) , 121-133
Antioxidant Hydrogel-Based Transdermal Drug Delivery Patch for Reactive Oxygen Species- and MyD88-Targeted Management of Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disorder driven by skin barrier dysfunction, immune dysregulation, a self-perpetuating cycle of inflammation and oxidative stress. Current therapies often target either oxidative stress or inflammation, yielding suboptimal outcomes. To overcome this, we developed Ce@iMyD88, a synergistic nanozyme, conjugating mesoporous cerium oxide nanoparticles with a MyD88 inhibitor (iMyD88), engineered to simultaneously scavenge reactive oxygen species (ROS) and suppress MyD88/NF-κB-mediated inflammatory signaling. Encapsulation in a lignin-based hydrogel provided biocompatibility, stability, and intrinsic antioxidant properties. In vitro, Ce@iMyD88 neutralizes superoxide, hydrogen peroxide, hydroxyl radicals, and attenuated ROS/proinflammatory cytokine expression in 2,4-dinitrochlorobenzene (DNCB)/H2O2-stimulated HaCaT keratinocytes. In vivo, applications in DNCB-induced AD and H2O2-challenged mice reduced epidermal thickness, mast cell infiltration, and restored skin barrier integrity. Compared with monotherapies, Ce@iMyD88 hydrogels markedly alleviated oxidative stress and inhibited MyD88/NF-κB signaling, reducing lesion severity and providing a precise strategy for managing inflammatory skin diseases through integrated nanoscale interventions.
- 15 October 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (43) , 58337-58345
H2O2 Self-Supplying CaO2 Nanoplatform Induces Ca2+ Overload Combined with Chemodynamic Therapy to Enhance Cancer Immunotherapy
Integrating chemodynamic therapy (CDT) with Ca2+ overload offers a potent strategy for enhancing cancer immunotherapy. However, the effectiveness of this approach is significantly constrained by the scarce availability of H2O2 in solid tumors. Here, we engineered a nanoplatform based on CaO2 nanoparticles (NPs) capable of encapsulating curcumin (CUR) and self-supplying H2O2 for synergistic CDT-augmented antitumor immunotherapy (CaO2@CUR@ZIF-Cu, denoted as CCZC). In the acidic tumor microenvironment, CCZC disintegrated to release CUR and copper(II) ions (Cu2+), revealing the core CaO2 NPs. CDT was amplified by escalating hydroxyl radical (•OH) production through a Fenton-like reaction mediated by H2O2 from the hydrolysis of CaO2 NPs. Ca2+ sourced from CaO2 NPs and CUR, an initiator of Ca2+ overload, induced Ca2+ overload in tumor cells, thereby promoting apoptosis. Subsequently, apoptotic tumor cells released tumor-associated antigens and pro-inflammatory cytokines, triggering adaptive immune responses and enhancing antitumor immunotherapy effects. In vivo experiments demonstrated that the intratumoral administration of CCZC displayed significant inhibitory effects, with an inhibition rate of up to 78% on B16-OVA-tumor-bearing mice compared to untreated. Moreover, an elevated proportion of mature dendritic cells were observed in the tumor-draining lymph nodes, along with an increase in cytotoxic T lymphocytes in the spleen. These findings suggest that our engineered nanoplatform effectively curtailed tumor growth via enhanced cancer immunotherapy by synergizing Ca2+ overload and CDT, proposing a novel strategy for synergistic cancer treatment.
- 15 October 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (43) , 58337-58345
H2O2 Self-Supplying CaO2 Nanoplatform Induces Ca2+ Overload Combined with Chemodynamic Therapy to Enhance Cancer Immunotherapy
Integrating chemodynamic therapy (CDT) with Ca2+ overload offers a potent strategy for enhancing cancer immunotherapy. However, the effectiveness of this approach is significantly constrained by the scarce availability of H2O2 in solid tumors. Here, we engineered a nanoplatform based on CaO2 nanoparticles (NPs) capable of encapsulating curcumin (CUR) and self-supplying H2O2 for synergistic CDT-augmented antitumor immunotherapy (CaO2@CUR@ZIF-Cu, denoted as CCZC). In the acidic tumor microenvironment, CCZC disintegrated to release CUR and copper(II) ions (Cu2+), revealing the core CaO2 NPs. CDT was amplified by escalating hydroxyl radical (•OH) production through a Fenton-like reaction mediated by H2O2 from the hydrolysis of CaO2 NPs. Ca2+ sourced from CaO2 NPs and CUR, an initiator of Ca2+ overload, induced Ca2+ overload in tumor cells, thereby promoting apoptosis. Subsequently, apoptotic tumor cells released tumor-associated antigens and pro-inflammatory cytokines, triggering adaptive immune responses and enhancing antitumor immunotherapy effects. In vivo experiments demonstrated that the intratumoral administration of CCZC displayed significant inhibitory effects, with an inhibition rate of up to 78% on B16-OVA-tumor-bearing mice compared to untreated. Moreover, an elevated proportion of mature dendritic cells were observed in the tumor-draining lymph nodes, along with an increase in cytotoxic T lymphocytes in the spleen. These findings suggest that our engineered nanoplatform effectively curtailed tumor growth via enhanced cancer immunotherapy by synergizing Ca2+ overload and CDT, proposing a novel strategy for synergistic cancer treatment.
- 23 August 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (35) , 45917-45928
High Cellular Internalization of Virus-Like Mesoporous Silica Nanoparticles Enhances Adaptive Antigen-Specific Immune Responses against Cancer
Effective activation of an antigen-specific immune response hinges upon the intracellular delivery of cancer antigens to antigen-presenting cells (APCs), marking the initial stride in cancer vaccine development. Leveraging biomimetic topological morphology, we employed virus-like mesoporous silica nanoparticles (VMSNs) coloaded with antigens and toll-like receptor 9 (TLR9) agonists to craft a potent cancer vaccine. Our VMSNs could be efficiently internalized by APCs to a greater extent than their nonviral structured counterparts, thereby promoting the activation of APCs by upregulating the TLR9 pathway and cross-presenting ovalbumin (OVA) epitopes. In in vivo animal study, VMSN-based nanovaccines triggered substantial CD4+ and CD8+ lymphocyte populations in both lymph nodes and spleen while inducing the effector memory of adaptive T cells. Consequently, VMSN-based nanovaccines suppressed tumor progression and increased the survival rate of B16-OVA-bearing mice in both prophylactic and therapeutic studies. The combination of immune checkpoint blockade (ICB) with the VMSN-based nanovaccine has synergistic effects in significantly preventing tumor progression under therapeutic conditions. These findings highlight the potential of viral structure-mimicking mesoporous silica nanoparticles as promising candidates for antigen-delivering nanocarriers in vaccine development.
- 23 August 2024
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 16 (35) , 45917-45928
High Cellular Internalization of Virus-Like Mesoporous Silica Nanoparticles Enhances Adaptive Antigen-Specific Immune Responses against Cancer
Effective activation of an antigen-specific immune response hinges upon the intracellular delivery of cancer antigens to antigen-presenting cells (APCs), marking the initial stride in cancer vaccine development. Leveraging biomimetic topological morphology, we employed virus-like mesoporous silica nanoparticles (VMSNs) coloaded with antigens and toll-like receptor 9 (TLR9) agonists to craft a potent cancer vaccine. Our VMSNs could be efficiently internalized by APCs to a greater extent than their nonviral structured counterparts, thereby promoting the activation of APCs by upregulating the TLR9 pathway and cross-presenting ovalbumin (OVA) epitopes. In in vivo animal study, VMSN-based nanovaccines triggered substantial CD4+ and CD8+ lymphocyte populations in both lymph nodes and spleen while inducing the effector memory of adaptive T cells. Consequently, VMSN-based nanovaccines suppressed tumor progression and increased the survival rate of B16-OVA-bearing mice in both prophylactic and therapeutic studies. The combination of immune checkpoint blockade (ICB) with the VMSN-based nanovaccine has synergistic effects in significantly preventing tumor progression under therapeutic conditions. These findings highlight the potential of viral structure-mimicking mesoporous silica nanoparticles as promising candidates for antigen-delivering nanocarriers in vaccine development.
- Open Access
- 2 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Immunosuppressive biomaterial-based therapeutic vaccine to treat multiple sclerosis via re-establishing immune tolerance
Current therapies for autoimmune diseases, such as multiple sclerosis (MS), induce broad suppression of the immune system, potentially promoting opportunistic infections. Here, we report an immunosuppressive biomaterial-based therapeutic vaccine carrying self-antigen and tolerance-inducing inorganic nanoparticles to treat experimental autoimmune encephalomyelitis (EAE), a mouse model mimicking human MS. Immunization with self-antigen-loaded mesoporous nanoparticles generates Foxp3+regulatory T-cells in spleen and systemic immune tolerance in EAE mice, reducing central nervous system-infiltrating antigen-presenting cells (APCs) and autoreactive CD4+T-cells. Introducing reactive oxygen species (ROS)-scavenging cerium oxide nanoparticles (CeNP) to self-antigen-loaded nanovaccine additionally suppresses activation of APCs and enhances antigen-specific immune tolerance, inducing recovery in mice from complete paralysis at the late, chronic stage of EAE, which shows similarity to chronic human MS. This study clearly shows that the ROS-scavenging capability of catalytic inorganic nanoparticles could be utilized to enhance tolerogenic features in APCs, leading to antigen-specific immune tolerance, which could be exploited in treating MS.
- 2 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-15
Open AccessImmunosuppressive biomaterial-based therapeutic vaccine to treat multiple sclerosis via re-establishing immune tolerance
Current therapies for autoimmune diseases, such as multiple sclerosis (MS), induce broad suppression of the immune system, potentially promoting opportunistic infections. Here, we report an immunosuppressive biomaterial-based therapeutic vaccine carrying self-antigen and tolerance-inducing inorganic nanoparticles to treat experimental autoimmune encephalomyelitis (EAE), a mouse model mimicking human MS. Immunization with self-antigen-loaded mesoporous nanoparticles generates Foxp3+regulatory T-cells in spleen and systemic immune tolerance in EAE mice, reducing central nervous system-infiltrating antigen-presenting cells (APCs) and autoreactive CD4+T-cells. Introducing reactive oxygen species (ROS)-scavenging cerium oxide nanoparticles (CeNP) to self-antigen-loaded nanovaccine additionally suppresses activation of APCs and enhances antigen-specific immune tolerance, inducing recovery in mice from complete paralysis at the late, chronic stage of EAE, which shows similarity to chronic human MS. This study clearly shows that the ROS-scavenging capability of catalytic inorganic nanoparticles could be utilized to enhance tolerogenic features in APCs, leading to antigen-specific immune tolerance, which could be exploited in treating MS.
- Open Access
- 26 March 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (4) , 709
Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment
Despite the potential of hydrogel-based localized cancer therapies, their efficacy can be limited by cancer recurrence. Therefore, it is of great significance to develop a hydrogel system that can provoke robust and durable immune response in the human body. This study has developed an injectable protein-polymer-based porous hydrogel network composed of lysozyme and poly(ε-caprolactone-co-lactide)-b-poly(ethylene glycol)-b-poly(ε-caprolactone-co-lactide (PCLA) (Lys-PCLA) bioconjugate for the active recruitment dendritic cells (DCs). The Lys-PCLA bioconjugates are prepared using thiol-ene reaction between thiolated lysozyme (Lys-SH) and acrylated PCLA (PCLA-Ac). The free-flowing Lys-PCLA bioconjugate sols at low temperature transformed to immovable gel at the physiological condition and exhibited stability upon dilution with buffers. According to the in vitro toxicity test, the Lys-PCLA bioconjugate and PCLA copolymer were non-toxic to RAW 263.7 cells at higher concentrations (1000 µg/mL). In addition, subcutaneous administration of Lys-PCLA bioconjugate sols formed stable hydrogel depot instantly, which suggested the in situ gel forming ability of the bioconjugate. Moreover, the Lys-PCLA bioconjugate hydrogel depot formed at the interface between subcutaneous tissue and dermis layers allowed the active migration and recruitment of DCs. As suggested by these results, the in-situ forming injectable Lys-PCLA bioconjugate hydrogel depot may serve as an implantable immune niche for the recruitment and modification of DCs.
- 26 March 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (4) , 709
Open AccessInjectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment
Despite the potential of hydrogel-based localized cancer therapies, their efficacy can be limited by cancer recurrence. Therefore, it is of great significance to develop a hydrogel system that can provoke robust and durable immune response in the human body. This study has developed an injectable protein-polymer-based porous hydrogel network composed of lysozyme and poly(ε-caprolactone-co-lactide)-b-poly(ethylene glycol)-b-poly(ε-caprolactone-co-lactide (PCLA) (Lys-PCLA) bioconjugate for the active recruitment dendritic cells (DCs). The Lys-PCLA bioconjugates are prepared using thiol-ene reaction between thiolated lysozyme (Lys-SH) and acrylated PCLA (PCLA-Ac). The free-flowing Lys-PCLA bioconjugate sols at low temperature transformed to immovable gel at the physiological condition and exhibited stability upon dilution with buffers. According to the in vitro toxicity test, the Lys-PCLA bioconjugate and PCLA copolymer were non-toxic to RAW 263.7 cells at higher concentrations (1000 µg/mL). In addition, subcutaneous administration of Lys-PCLA bioconjugate sols formed stable hydrogel depot instantly, which suggested the in situ gel forming ability of the bioconjugate. Moreover, the Lys-PCLA bioconjugate hydrogel depot formed at the interface between subcutaneous tissue and dermis layers allowed the active migration and recruitment of DCs. As suggested by these results, the in-situ forming injectable Lys-PCLA bioconjugate hydrogel depot may serve as an implantable immune niche for the recruitment and modification of DCs.